IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum resistant epithelial ovarian cancer (EOC) patients (pts).

被引：1

作者：

Moore, Kathleen N.

Martin, Lainie P.

Matulonis, Ursula A.

Konner, Jason A.

Seward, Shelly Marie

Bauer, Todd Michael

O'Malley, David M.

Perez, Raymond P.

Jeong, Woondong

Zhou, Yinghui

Kirby, Maurice William

Mohanavelu, Satishkumar

Ruiz-Soto, Rodrigo

Birrer, Michael J.

机构：

[1] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA

[2] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] Wayne State Univ, Karmanos Canc Inst, Huntington Woods, MI USA

[6] Sarah Cannon Res Inst, Nashville, TN USA

[7] Tennessee Oncol PLLC, Nashville, TN USA

[8] Ohio State Univ, Coll Med, Columbus, OH 43210 USA

[9] Univ Kansas, Fairway, KS USA

[10] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA

[11] ImmunoGen Inc, Waltham, MA USA

[12] Massachusetts Gen Hosp, Dana Farber Canc Ctr, Boston, MA 02114 USA

来源：

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.5567

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5567

引用

页数：3